BioSpace News Archive

Business

Ecolab Delivers Very Strong First Quarter Performance

Ecolab Delivers Very Strong First Quarter Performance.

April 30, 2024
·
30 min read
Business

Appendix 4C – Q3 FY24 Quarterly Cash Flow Report

Alterity Therapeutics released its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 31 March 2024.

April 30, 2024
·
7 min read
Business

MiNK to Provide Corporate Update and First Quarter 2024 Financial Report

MiNK Therapeutics, Inc. announced that the Company will release its first quarter 2024 financial results before the market opens on Tuesday, May 14, 2024.

April 30, 2024
·
1 min read
Business

BioRestorative Therapies Announces Transformative Commercial Agreement with Cartessa, a Global Leader in Medical Aesthetics Technology

BioRestorative Therapies, Inc. announced that it has entered into a five-year exclusive supply agreement with Cartessa Aesthetics, LLC, a leading North American based aesthetic company focused on delivering best-in-class technologies and unparalleled end-to-end professional customer support.

April 30, 2024
·
7 min read
Business

Pixelgen Technologies Appoints Mostafa Ronaghi to Scientific Advisory Board

Pixelgen Technologies announced today the appointment of Mostafa Ronaghi , Ph.D., to its Scientific Advisory Board.

April 30, 2024
·
2 min read
Drug Development

INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer’s Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three Years

INmune Bio Inc. is pleased to share an update on two patients from the Phase 1b trial completed in 2021 who have continued to receive XPro™ for treatment of Alzheimer’s Disease (AD).

April 30, 2024
·
5 min read
BioForest

Shape Therapeutics to Showcase RNA Editing in the Brain and Validation of their Stable AAV Producer Cell Line at ASGCT 2024

Shape Therapeutics today announced its upcoming oral presentations at the 27th American Society for Gene and Cell Therapy (ASGCT) Annual Meeting taking place May 7-11 in Baltimore, MD.

April 30, 2024
·
1 min read
Pharm Country

In Vivo Efficacy of Matinas BioPharma’s Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy

Matinas BioPharma Holdings, Inc. announces that MAT2203, its oral formulation of the potent antifungal amphotericin B, demonstrated efficacy compared with placebo in treating the pulmonary mucormycosis fungal infections Rhizopus delemar and M. circinelloides f. jenssenii in immunosuppressed mice.

April 30, 2024
·
6 min read
Drug Development

Soleno Therapeutics Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to the Natural History of Prader-Willi Syndrome

Soleno Therapeutics, Inc. today announced the publication of the comparison of results from the Company’s Phase 3 placebo-controlled study (C601) and open-label extension study (C602) evaluating investigational, once-daily DCCR (Diazoxide Choline) Extended-Release tablets in patients with Prader-Willi syndrome.

April 30, 2024
·
6 min read
Drug Development

Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML)

Senti Biosciences, Inc. today announced the publication of preclinical data demonstrating the ability of natural killer (NK) cells engineered with multi-input Gene Circuits to selectively target and eliminate leukemic cells, including both blasts and leukemic stem cells, while sparing healthy stem cells. The data was published in Cell Reports on April 25, 2024.

April 30, 2024
·
8 min read